NCT05607173View on ClinicalTrials.gov

A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions
Hepatic Function Abnormal
Interventions
DRUG

Fexinidazole (HOE239)

Route of administration: oral; pharmaceutical form: tablet

Trial Locations (2)

1612

Investigational Site Number: 100-0001, Sofia

Unknown

Investigational site 250-0001, Rennes

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05607173 - A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter